Volume 26, Number 1—January 2020
Research Letter
Autochthonous Human Fascioliasis, Belgium
Sandrine Milas1
, Camelia Rossi, Ivan Philippart, Pierre Dorny, and Emmanuel Bottieau
, Camelia Rossi, Ivan Philippart, Pierre Dorny, and Emmanuel Bottieau
Table
Clinical, laboratory, and radiologic features of 2 autochthonous cases of human fascioliasis, Mons, Belgium, 2008–2009*
| Features | Case 1 | Case 2 |
|---|---|---|
| Patient age, y/sex | 72/M | 59/F |
| Date of initial examination |
Nov 2008 |
Dec 2008 |
| Laboratory tests, date | ||
| Eosinophil cell count/mL (% leukocytes)† | ||
| Nov 2008 | 9,688 (56) | ND |
| Dec 2008 | 7,504 (56) | 6,750 (43) |
| Mar 2009 | 8,830 (56.6) | 8,525 (55) |
| 1 mo after triclabendazole | 627 (10.8) | 3,526 (41) |
| 5 mo after triclabendazole | 512 (8.4) | 812 (14.5) |
| Aspartate aminotransferases, IU/L‡ | ||
| Nov 2008 | 53 | ND |
| Dec 2008 | 30 | 21 |
| Mar 2009 | 25 | 23 |
| 1 mo after triclabendazole | 26 | 32 |
| 5 mo after triclabendazole |
17 |
ND |
| Serologic test (method), date | Dec 2008 | Jan 2009 |
| Ascaris spp. (immunodiffusion) | – | – |
| Echinococcus granulosus (ELISA) | – | – |
| Echinococcus multilocularis (ELISA) | – | ND |
| Toxocara spp. (ELISA) | – | – |
| Taenia solium | ND | – |
| Trichinella spiralis (ELISA) | + | – |
| Fasciola (indirect hemagglutination), Mar 2009§ | 1/640 | 1/2,560 |
| 1 mo. after triclabendazole | 1/640 | ND |
| 5 mo. after triclabendazole | 1/320 | 1/320 |
| Abdominal CT, date | Nov 2008, multiple hypodense liver nodules | Mar 2009, multiple hypodense liver nodules |
| Liver biopsy, date |
Dec 2008, chronic active hepatitis with acute necrosis, presence of eosinophils in portal spaces |
ND |
| *Both case-patients had an early acute phase of disease during Sep–Dec 2008 with high fever, abdominal pain, generalized itching, and urticarial skin rash. Both cases then had a later disease phase during Nov 2008–Mar 2009 with persistent fatigue and weight loss. CT, computed tomography; IU, International Units; ND, not done; –, negative; +, positive.
†Normal values, 0–400/mL (<7%).
‡Normal values 10–40 IU/L.
§Normal value <1/320. |
||
1Current affiliation: University Center of Charleroi, Charleroi, Belgium.
Page created: December 18, 2019
Page updated: December 18, 2019
Page reviewed: December 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.